Role of Iron Chelators in Mucormycosis.
作者信息
Mahalmani Vidya, Sarma Phulen, Prakash Ajay, Medhi Bikash
机构信息
Department of Pharmacology, Jawaharlal Nehru Medical College, Kaher, Belagavi, Karnataka, India.
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2021 Jul-Aug;53(4):261-263. doi: 10.4103/ijp.ijp_604_21.
Abstract
摘要
相似文献
1
Role of Iron Chelators in Mucormycosis.铁螯合剂在毛霉病中的作用。
Indian J Pharmacol. 2021 Jul-Aug;53(4):261-263. doi: 10.4103/ijp.ijp_604_21.
2
COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy.新型冠状病毒肺炎相关毛霉菌病，宿主铁同化：益生菌可能是一种新型疗法。
Indian J Pharmacol. 2021 Sep-Oct;53(5):415-416. doi: 10.4103/ijp.ijp_406_21.
3
Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review.乳铁蛋白，一种潜在的铁螯合剂，作为毛霉病的辅助治疗——全面综述。
Int J Biol Macromol. 2021 Sep 30;187:988-998. doi: 10.1016/j.ijbiomac.2021.07.156. Epub 2021 Jul 27.
4
The iron chelator deferasirox protects mice from mucormycosis through iron starvation.铁螯合剂地拉罗司通过铁饥饿保护小鼠免受毛霉菌病侵害。
J Clin Invest. 2007 Sep;117(9):2649-57. doi: 10.1172/JCI32338.
5
Survival in rhinocerebral mucormycosis: is iron the key?鼻脑型毛霉菌病的生存：铁是关键吗？
Neurol India. 2007 Oct-Dec;55(4):416. doi: 10.4103/0028-3886.37101.
6
[Iron and invasive fungal infection].[铁与侵袭性真菌感染]
Rev Iberoam Micol. 2013 Oct-Dec;30(4):217-25. doi: 10.1016/j.riam.2013.04.002. Epub 2013 May 14.
7
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.去铁胺可增强根霉的生长和致病性，而羟基吡啶酮螯合剂则无此作用。
Kidney Int. 1994 Mar;45(3):667-71. doi: 10.1038/ki.1994.89.
8
Should statins be considered for the management of mucormycosis in COVID-19?在新冠病毒感染（COVID-19）中，是否应考虑使用他汀类药物来治疗毛霉菌病？
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102162. doi: 10.1016/j.dsx.2021.05.035. Epub 2021 Jun 5.
9
Mucormycosis in COVID-19 recovered patients.新冠康复患者中的毛霉菌病
J Med Virol. 2022 Apr;94(4):1272-1273. doi: 10.1002/jmv.27522. Epub 2021 Dec 18.
10
Palatal mucormycosis in a patient with SARS-CoV-2 infection.一名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者发生腭部毛霉菌病。
CMAJ. 2021 Aug 16;193(32):E1254. doi: 10.1503/cmaj.211026.
引用本文的文献
1
Role of the putative gene in normal germination of spores and virulence of the .假定基因在孢子正常萌发及该菌毒力中的作用。 （你提供的原文最后似乎不完整，这里是根据现有内容尽量完整翻译的）
Microb Cell. 2025 Aug 12;12:195-209. doi: 10.15698/mic2025.08.856. eCollection 2025.
2
Investigating the Hepcidin Gene Polymorphisms in COVID-19-Associated Mucormycosis Susceptibility: A Clinical-Laboratory Study.新冠病毒相关毛霉菌病易感性中铁调素基因多态性的研究：一项临床实验室研究
Iran J Med Sci. 2024 Jul 1;49(7):450-460. doi: 10.30476/ijms.2023.99589.3167. eCollection 2024 Jul.
3
Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.新型冠状病毒肺炎大流行期间毛霉病的增多及面临的挑战
Curr Med Mycol. 2023 Mar;9(1):44-55. doi: 10.18502/cmm.2023.345032.1400.
4
Coping With Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity.应对压力：细胞因子 GDF-15 作为 COVID-19 严重程度的生物标志物。
Front Immunol. 2022 Feb 16;13:820350. doi: 10.3389/fimmu.2022.820350. eCollection 2022.
5
Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach.毛霉菌病与 COVID-19 大流行：临床和诊断方法。
J Infect Public Health. 2022 Apr;15(4):466-479. doi: 10.1016/j.jiph.2022.02.007. Epub 2022 Feb 18.
6
COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.新型冠状病毒肺炎相关毛霉病：早期快速诊断的技术进展
3 Biotech. 2022 Jan;12(1):6. doi: 10.1007/s13205-021-03080-4. Epub 2021 Dec 6.
7
Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis.血清铁蛋白作为 COVID-19 的预测生物标志物：系统评价、荟萃分析和荟萃回归分析。
J Crit Care. 2022 Feb;67:172-181. doi: 10.1016/j.jcrc.2021.09.023. Epub 2021 Nov 20.
本文引用的文献
1
Mucormycosis with orbital compartment syndrome in a patient with COVID-19.COVID-19 患者合并眼窝间隔综合征的毛霉菌病。
Am J Emerg Med. 2021 Apr;42:264.e5-264.e8. doi: 10.1016/j.ajem.2020.09.032. Epub 2020 Sep 16.
2
Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.皮质类固醇在新冠病毒疾病管理中的作用：一项系统评价及临床医生视角
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):971-978. doi: 10.1016/j.dsx.2020.06.054. Epub 2020 Jun 27.
3
Invasive and Non-Invasive Fungal Rhinosinusitis-A Review and Update of the Evidence.侵袭性和非侵袭性真菌性鼻-鼻窦炎-证据的回顾和更新。
Medicina (Kaunas). 2019 Jun 28;55(7):319. doi: 10.3390/medicina55070319.
4
Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India.毛霉病：印度五年间与致命敌人的斗争
J Fungi (Basel). 2018 Apr 6;4(2):46. doi: 10.3390/jof4020046.
5
A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).法国毛霉病的全球分析：RetroZygo 研究（2005-2007 年）。
Clin Infect Dis. 2012 Feb;54 Suppl 1:S35-43. doi: 10.1093/cid/cir880.
6
Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis.应对新出现病原体的挑战：亨利·舒勒 41&9 基金会国际毛霉病论坛。
Clin Infect Dis. 2012 Feb;54 Suppl 1:S1-4. doi: 10.1093/cid/cir862.
7
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.去铁酮-两性霉素 B 脂质体治疗毛霉病（DEFEAT Mucor）研究：一项随机、双盲、安慰剂对照试验。
J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.
8
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.欧洲接合菌病：欧洲医学真菌学会（ECMM）接合菌病工作组 2005 年至 2007 年登记的 230 例病例分析。
Clin Microbiol Infect. 2011 Dec;17(12):1859-67. doi: 10.1111/j.1469-0691.2010.03456.x. Epub 2011 Jul 1.
9
Forty-one recent cases of invasive zygomycosis from a global clinical registry.全球临床注册中心的 41 例侵袭性接合菌病近期病例。
J Antimicrob Chemother. 2010 Feb;65(2):296-302. doi: 10.1093/jac/dkp430. Epub 2009 Dec 11.
10
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.黑腹果蝇作为剖析接合菌病免疫发病机制的模式宿主。
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9367-72. doi: 10.1073/pnas.0709578105. Epub 2008 Jun 26.
Zotero 插件